Daclizumab therapy for children with corticosteroid-resistant acute graft-vs.-host disease

Pediatric Transplantation

Volumn 13, Issue 3, 2009, Pages 332-337

  Schechter, Tal ^a   Afzal, Samina ^a   Finkelstein, Yaron ^a   Koren, Gideon ^a,b   Doyle, John ^a,b   Dupuis, L Lee ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

Author keywords

Acute graft vs. host disease; Daclizumab; Pediatrics

Indexed keywords

DACLIZUMAB; INFLIXIMAB; METHYLPREDNISOLONE;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INFANT; INTESTINE; MALE; MORTALITY; PRESCHOOL CHILD; PROPHYLAXIS; REACTIVE ARTHRITIS; SCHOOL CHILD; SURVIVAL; TREATMENT RESPONSE;

ACUTE DISEASE; ADOLESCENT; ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; FEMALE; GLUCOCORTICOIDS; GRAFT VS HOST DISEASE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INFANT; MALE;

EID: 64149091117     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2008.00959.x     Document Type: Article

References (31)

1. Storb R, Pepe M, Anasetti C, et al. What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? Blood 1990 : 76 : 1037 1045.
2. Nademanee A, Schmidt GM, Parker P, et al. The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone. Blood 1995 : 86 : 1228 1234.
3. Carpenter PA, Sanders JE. Steroid-refractory graft-vs.-host disease: Past, present and future. Pediatr Transplant 2003 : 7 (Suppl. 3 19 31.
4. MacMillan ML, Weisdorf DJ, Wagner JE, et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: Comparison of grading systems. Biol Blood Marrow Transplant 2002 : 8 : 387 394.
5. Ruutu T, Niederwieser D, Gratwohl A, Apperley JF. A survey of the prophylaxis and treatment of acute GVHD in Europe: A report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT. Bone Marrow Transplant 1997 : 19 : 759 764.
6. Bruner RJ, Farag SS. Monoclonal antibodies for the prevention and treatment of graft-versus-host disease. Semin Oncol 2003 : 30 : 509 519.
7. Bordigoni P, Dimicoli S, Clement L, et al. Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease. Br J Haematol 2006 : 135 : 382 385.
8. Willenbacher W, Basara N, Blau IW, Fauser AA, Kiehl MG. Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab. Br J Haematol 2001 : 112 : 820 823.
9. Srinivasan R, Chakrabarti S, Walsh T, et al. Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis. Br J Haematol 2004 : 124 : 777 786.
10. Przepiorka D, Kernan NA, Ippoliti C, et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000 : 95 : 83 89.
11. Teachey DT, Bickert B, Bunin N. Daclizumab for children with corticosteroid refractory graft-versus-host disease. Bone Marrow Transplant 2006 : 37 : 95 99.
12. Kamble R, Oholendt M, Carrum G. Rituximab responsive refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2006 : 12 : 1201 1202 (letter).
13. Jacobsohn DA, Hallick J, Anders V, McMillan S, Morris L, Vogelsang GB. Infliximab for steroid-refractory acute GVHD: A case series. Am J Hematol 2003 : 74 : 119 124.
14. Couriel D, Saliba R, Hicks K, et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 2004 : 104 : 649 654.
15. Rivkina AM, Stump LS. Infliximab in graft-versus-host disease. Am J Health Syst Pharm 2002 : 59 : 1271 1275.
16. Rodriguez V, Anderson PM, Trotz BA, Arndt CA, Allen JA, Khan SP. Use of infliximab-daclizumab combination for the treatment of acute and chronic graft-versus-host disease of the liver and gut. Pediatr Blood Cancer 2007 : 49 : 212 215.
17. Patriarca F, Sperotto A, Damiani D, et al. Infliximab treatment for steroid-refractory acute graft-versus-host disease. Haematologica 2004 : 89 : 1352 1359.
18. Massenkeil G, Rackwitz S, Genvresse I, Rosen O, Dorken B, Arnold R. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplant 2002 : 30 : 899 903.
19. Funke VA, de MedeirosCR, Setubal DC, et al. Therapy for severe refractory acute graft-versus-host disease with basiliximab, a selective interleukin-2 receptor antagonist. Bone Marrow Transplant 2006 : 37 : 961 965.
20. Moreira V, Bonfim C, Bitencourt M, et al. Therapy for refractory acute graft versus host disease (AGVHD) with basiliximab (BAMAB) - A selective interleukin-2 receptor (IL-2R) antagonist. Biol Blood Marrow Transplant 2004 : 10 (Suppl. 1 21 (abstract).
21. Carpenter PA, Lowder J, Johnston L, et al. A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2005 : 11 : 465 471.
22. Pinana JL, Valcarcel D, Martino R, et al. Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2006 : 12 : 1135 1141.
23. Macmillan ML, Couriel D, Weisdorf DJ, et al. A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood 2007 : 109 : 2657 2662.
24. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974 : 18 : 295 304.
25. Thomas ED, Storb R, Clift RA, et al. Bone-marrow transplantation (second of two parts). N Engl J Med 1975 : 292 : 895 902.
26. Shaughnessy PJ, Bachier C, Grimley M, et al. Denileukin difitox for the treatment of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 2005 : 11 : 188 193.
27. MacMillan ML, Weisdorf DJ, Davies SM, et al. Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 2002 : 8 : 40 46.
28. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: Initial treatment. Blood 1990 : 76 : 1464 1472.
29. Zenapax Product Monograph. Nutley, NJ : Hoffman-LaRoche Inc., 2005.
30. Buda-Okreglak EM, Drabick JJ, Delaney NR. Proinflammatory syndrome mimicking acute rheumatoid arthritis in a patient with Waldenstrom's macroglobulinemia treated with rituximab. Ann Hematol 2004 : 83 : 117 119.
31. Marty FM, Lee SJ, Fahey MM, et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: A cohort study. Blood 2003 : 102 : 2768 2776.